President Putin to ease procedure for drug certification in Russia

26 June 2018

Russia’s President Vladimir Putin has ordered the national government to ease the process of certification of foreign drugs in Russia this year, according to recent statements of the Russian Presidential Administration, reports The Pharma Letter’s local correspondent.

According to recent statements from Mr Putin, certification of drugs in Russia is greatly delayed due to the bureaucracy in the registration system.

Mr Putin said he receives numerous complaints from global drugmakers operating in Russia, who say the procedure for obtaining a certificate for the production and sale of drugs in Russia may vary in the range of 1-1.5 years.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK